Mitochondrial Gene Scoring System for Hepatocellular Carcinoma
Author Information
Author(s): Ma Jian-ying, Wei Wei, Wang Yi-xian, Zhao Zhen-yu, Xiong Zhen-yu, Mei Jie, Wu Wen-ze, Guo Jia-wei
Primary Institution: Yangtze University
Hypothesis
Can mitochondrial gene scoring systems predict prognosis and TACE non-response in hepatocellular carcinoma patients?
Conclusion
The RPS and RDS are important tools for predicting outcomes and guiding treatment decisions in hepatocellular carcinoma patients.
Supporting Evidence
- The RPS accurately predicts 1-5 year survival rates in HCC patients.
- Patients with higher RDS values are more likely to experience TACE non-response.
- Lower RDS is associated with better responses to immunotherapy.
- ACSM2A is identified as a potential therapeutic target in HCC.
Takeaway
This study created two scoring systems to help doctors predict how well patients with liver cancer will respond to treatment and how long they might live.
Methodology
The study used machine learning algorithms and regression analyses to develop risk scores based on mitochondrial gene expression.
Potential Biases
Potential sample bias due to the limited number of patients surviving beyond five years in the validation dataset.
Limitations
The study relied on publicly available datasets, which may not represent the full diversity of hepatocellular carcinoma cases.
Participant Demographics
Patients with hepatocellular carcinoma, including various stages and treatment responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website